SCHEMBL4452596

SCHEMBL4452596

CNC(=O)[C@@H](NC(=O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1)C(c1ccccc1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 2/20 0.43
MAPK1 P28482 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.41
TACR1 P25103 2/20 0.40
KCNK9 Q9NPC2 1/20 0.40
MTTP P55157 1/20 0.39
ADAM17 P78536 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
TACR3 P29371 1/20 0.38
CTSL P07711 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4452601 1.00 L3MBTL1 (0.44) L3MBTL1MEN1KMT2ALMNAMAPK1
SCHEMBL4446922 0.91 CTSL (0.39) L3MBTL1MEN1KMT2ALMNAMAPK1
SCHEMBL4446927 0.91 CTSL (0.39) L3MBTL1MEN1KMT2ALMNAMAPK1
SCHEMBL13960116 0.90 CTSL (0.48) L3MBTL1MEN1KMT2ALMNAMAPK1
SCHEMBL4448518 0.90 L3MBTL1 (0.54) L3MBTL1MEN1KMT2ALMNAPKM
SCHEMBL4448522 0.90 L3MBTL1 (0.54) L3MBTL1MEN1KMT2ALMNAPKM
SCHEMBL4446680 0.88 LMNA (0.49) L3MBTL1MEN1KMT2ALMNAMAPK1
SCHEMBL4446676 0.88 LMNA (0.49) L3MBTL1MEN1KMT2ALMNAMAPK1
SCHEMBL4448633 0.87 CTSL (0.38) L3MBTL1MEN1KMT2ALMNAMAPK1
SCHEMBL4448639 0.87 CTSL (0.38) L3MBTL1MEN1KMT2ALMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012010-A1 Amino acid derivatives as calcium channel blockers NEUROMED PHRAMACEUTICALS LTD. (CA) 2009-01-08 US disclosed
US-20090012010-A1 Amino acid derivatives as calcium channel blockers NEUROMED PHRAMACEUTICALS LTD. (CA) 2009-01-08 US disclosed
US-20090012010-A1 Amino acid derivatives as calcium channel blockers NEUROMED PHRAMACEUTICALS LTD. (CA) 2009-01-08 US disclosed
WO-2008141446-A1 AMINO ACID DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012010-A1 Amino acid derivatives as calcium channel blockers CACNA1G, CACNA1H, CACNA1I L3MBTL1 1802/4885MEN1 1973/4885KMT2A 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.